ArticleInternational journal of molecular and cellular medicine2023
Biological Activity of Mouse OX40L-Igg Purified With Two Novel Resins.
Article in International journal of molecular and cellular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the important stimulating molecules for the function of T lymphocytes is tumor necrosis factor receptor OX40 (CD134), activated by its cognate ligand OX40L (CD134L, CD252). OX40L interactions have been proposed as a potential therapeutic target for treating infectious and non-infectious diseases. The main purpose of this study was to determine the potency of two novel resins MBI and MEP for the purification of OX40L-IgG fusion protein and the biological activities of this OX40L-IgG fusion protein. The biological activity of the OX40L-IgG purified by these resins compared with protein A sepharose resin. Mice treated with the same doses of the OX40L purified by the three resins showed a significant delay in tumor growth compared to the controls injected with PBS. Mice treated with the OX40L purified by MBI resin showed a significant delay in tumor cell (CT26) growth compared with mice injected with OX40L purified by other resins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.